MRNA
NASDAQModerna Inc.
News · 26 weeks100-45%
2026-04-192026-10-11
Mix4490d
- Insider14(32%)
- Market10(23%)
- Other8(18%)
- Analyst6(14%)
- SEC Filings5(11%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Moderna Inc.4 - Moderna, Inc. (0001682852) (Issuer)
- PRAI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost
- NEWSModerna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third quarter 2026 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a pioneer and leader in the field of mRNA medicine. Through the adva
- INSIDERSEC Form 4 filed by Moderna Inc.4 - Moderna, Inc. (0001682852) (Issuer)
- PR2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New HopeDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC
- INSIDERSEC Form 3 filed by Moderna Inc.3 - Moderna, Inc. (0001682852) (Issuer)
- PRModerna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Moderna, Inc. (NASDAQ:MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (NASDAQ:WBD) prior to market open on Friday, October 9, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by
- ANALYSTModerna downgraded by Citigroup with a new price targetCitigroup downgraded Moderna from Neutral to Sell and set a new price target of $80.00
- SECModerna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Moderna, Inc. (0001682852) (Filer)
- NEWSModerna Adds Chief Operating Officer Role as Company Expands into OncologyJuan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company.The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. The Company has also expanded the infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of Moderna's seaso
- NEWSModerna Announces Late-Breaking Data to be Presented at ESMO Congress 2026Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain.The presentation details are as follows:Presidential Symposium:LBA1
- INSIDERPresident Hoge Stephen exercised 152,905 shares at a strike of $12.21 and sold $11,691,420 worth of shares (80,575 units at $145.10) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 1,562,029 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- INSIDERChief Financial Officer Mock James M exercised 19,836 shares at a strike of $30.96 and sold $4,685,094 worth of shares (34,836 units at $134.49) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 59,375 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERPresident Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)4 - Moderna, Inc. (0001682852) (Issuer)
- ANALYSTModerna downgraded by Rothschild & Co Redburn with a new price targetRothschild & Co Redburn downgraded Moderna from Neutral to Sell and set a new price target of $81.00
- SECModerna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Moderna, Inc. (0001682852) (Filer)
- NEWSModerna to Present at Upcoming Conferences in September 2026CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ETBernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m. ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a pione
- INSIDERPresident Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation4 - Moderna, Inc. (0001682852) (Issuer)
MRNA FAQ
7 questionsWhat does Moderna Inc. do?
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with...Where does MRNA stock trade?
Moderna Inc. (MRNA) is listed on NASDAQ.What sector and industry is MRNA in?
Moderna Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Moderna Inc. go public?
Moderna Inc. (MRNA) completed its IPO in 2018.What are analysts saying about MRNA?
Moderna Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Sell on 2026-09-30. Recent price targets range from $2500.00 to $3400.00.What companies are similar to MRNA?
Notable peers in the same industry include MRK (Merck & Company Inc.), AZN (AstraZeneca PLC), PFE (Pfizer Inc.), GSK (GSK plc), BNTX (BioNTech SE). Compare MRNA side-by-side with any of them on Quantisnow.How can I track MRNA on Quantisnow?
Quantisnow aggregates Moderna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRNA to receive live email and push alerts on every new disclosure.